| Drug Name |
Ethambutol hydrochloride |
| Drug ID |
BADD_D00842 |
| Description |
Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.[L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048]
Ethambutol was granted FDA approval on 6 November 1967.[L31663] |
| Indications and Usage |
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis.[L31663] Ethambutol is commonly used in combination with [isoniazid], [rifampin], and [pyrazinamide].[L31743] |
| Marketing Status |
approved |
| ATC Code |
J04AK02 |
| DrugBank ID |
DB00330
|
| KEGG ID |
D00878
|
| MeSH ID |
D004977
|
| PubChem ID |
14051
|
| TTD Drug ID |
D08QME
|
| NDC Product Code |
42806-102; 68850-012; 68180-280; 68850-010; 70518-3662; 42806-101; 54879-002; 68084-280; 65691-0014; 68180-281; 70518-2691; 66406-0224; 50090-5140; 70518-2966; 54879-001 |
| UNII |
QE4VW5FO07
|
| Synonyms |
Ethambutol | Dexambutol | Etibi | EMB-Fatol | EMB Fatol | Etambutol Llorente | Llorente, Etambutol | Ethambutol Hydrochloride | Hydrochloride, Ethambutol | Myambutol | Miambutol | EMB-Hefa | EMB Hefa |
